196 related articles for article (PubMed ID: 25919900)
1. No evidence for predictors of response to atomoxetine treatment of attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder.
Harfterkamp M; van der Meer D; van der Loo-Neus G; Buitelaar JK; Minderaa RB; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2015 May; 25(4):372-5. PubMed ID: 25919900
[No Abstract] [Full Text] [Related]
2. Atomoxetine for attention deficit hyperactivity disorder in children and adolescents with autism: A systematic review and meta-analysis.
Patra S; Nebhinani N; Viswanathan A; Kirubakaran R
Autism Res; 2019 Apr; 12(4):542-552. PubMed ID: 30653855
[TBL] [Abstract][Full Text] [Related]
3. Effects of Atomoxetine in Individuals with Attention-Deficit/Hyperactivity Disorder and Low-Functioning Autism Spectrum Disorder.
Kilincaslan A; Mutluer TD; Pasabeyoglu B; Tutkunkardas MD; Mukaddes NM
J Child Adolesc Psychopharmacol; 2016 Nov; 26(9):798-806. PubMed ID: 27228116
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of Atomoxetine in the Treatment of Children With Encopresis.
Türkoğlu S; Bilgiç A; Uzun N
J Clin Psychopharmacol; 2015 Oct; 35(5):622-3. PubMed ID: 26110671
[No Abstract] [Full Text] [Related]
5. [Atomoxetine Treatment For Encopresis In A Child With Attention Deficit Hyperactivity Disorder].
Bozkurt H; Şahin S
Turk Psikiyatri Derg; 2016; 27(2):0. PubMed ID: 27482753
[TBL] [Abstract][Full Text] [Related]
6. Increased Frequency of Encopresis in a Child Diagnosed With Attention Deficit/Hyperactivity Disorder and Encopresis After Atomoxetine Use: A Case Report.
Yektaş Ç; Cansiz MA; Tufan AE
Clin Neuropharmacol; 2016; 39(4):212-3. PubMed ID: 27332628
[TBL] [Abstract][Full Text] [Related]
7. Atomoxetine in the Treatment of Adolescent With Trichotillomania and Attention-Deficit/Hyperactivity Disorder.
Türkoğlu S; Çetin FH
Clin Neuropharmacol; 2018; 41(2):84-85. PubMed ID: 29533364
[No Abstract] [Full Text] [Related]
8. Long-term treatment with atomoxetine for attention-deficit/hyperactivity disorder symptoms in children and adolescents with autism spectrum disorder: an open-label extension study.
Harfterkamp M; Buitelaar JK; Minderaa RB; van de Loo-Neus G; van der Gaag RJ; Hoekstra PJ
J Child Adolesc Psychopharmacol; 2013 Apr; 23(3):194-9. PubMed ID: 23578015
[TBL] [Abstract][Full Text] [Related]
9. A 1.5-Year Follow-Up of Parent Training and Atomoxetine for Attention-Deficit/Hyperactivity Disorder Symptoms and Noncompliant/Disruptive Behavior in Autism.
Arnold LE; Ober N; Aman MG; Handen B; Smith T; Pan X; Hyman SL; Hollway J; Lecavalier L; Page K; Rice R
J Child Adolesc Psychopharmacol; 2018 Jun; 28(5):322-330. PubMed ID: 29694241
[TBL] [Abstract][Full Text] [Related]
10. Raynaud's Phenomenon Related with Atomoxetine Treatment in a Child with Autism and Attention-Deficit/Hyperactivity Disorder.
Gülle ZN; Karayagmurlu A; Coskun M
J Child Adolesc Psychopharmacol; 2019 Oct; 29(8):649-650. PubMed ID: 31264893
[No Abstract] [Full Text] [Related]
11. [Atomoxetine for treatment of children and adolescents with ADHD].
Resen K; Pagsberg AK; Jörgens G
Ugeskr Laeger; 2014 Mar; 176(10A):. PubMed ID: 25350704
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of atomoxetine for symptoms of attention-deficit/hyperactivity disorder in children with a history of child abuse.
Sugimoto A; Suzuki Y; Endo T; Matsumoto K; Sugiyama T; Someya T
J Child Adolesc Psychopharmacol; 2015 Apr; 25(3):269-71. PubMed ID: 25885013
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind comparison of atomoxetine and placebo on response inhibition and interference control in children and adolescents with autism spectrum disorder and comorbid attention-deficit/hyperactivity disorder symptoms.
van der Meer JM; Harfterkamp M; van de Loo-Neus G; Althaus M; de Ruiter SW; Donders AR; de Sonneville LM; Buitelaar JK; Hoekstra PJ; Rommelse NN
J Clin Psychopharmacol; 2013 Dec; 33(6):824-7. PubMed ID: 24018545
[No Abstract] [Full Text] [Related]
14. Increased prefrontal hemodynamic change after atomoxetine administration in pediatric attention-deficit/hyperactivity disorder as measured by near-infrared spectroscopy.
Ota T; Iida J; Nakanishi Y; Sawada S; Matsuura H; Yamamuro K; Ueda S; Uratani M; Kishimoto N; Negoro H; Kishimoto T
Psychiatry Clin Neurosci; 2015 Mar; 69(3):161-70. PubMed ID: 25359429
[TBL] [Abstract][Full Text] [Related]
15. Atomoxetine Use in Attention-Deficit/Hyperactivity Disorder and Comorbid Tic Disorder in Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections.
Demirkaya SK; Demirkaya M; Yusufoğlu C; Akın E
J Child Adolesc Psychopharmacol; 2017 Feb; 27(1):104-105. PubMed ID: 27315236
[TBL] [Abstract][Full Text] [Related]
16. Atomoxetine Pharmacogenetics: Lessons Learned.
Ermer D; Vik T
S D Med; 2017 Jul; 70(7):294-296. PubMed ID: 28806024
[No Abstract] [Full Text] [Related]
17. The Effect of Atomoxetin Use in the Treatment of Attention-Deficit/Hyperactivity Disorder on the Symptoms of Restless Legs Syndrome: A Case Report.
Baykal S; Karakurt MN
Clin Neuropharmacol; 2017; 40(2):93-94. PubMed ID: 28195837
[TBL] [Abstract][Full Text] [Related]
18. [Reconsider the diagnosis and treatment approach for ADHD].
Jacobsson L; Hägglöf B
Lakartidningen; 2015 Feb; 112():. PubMed ID: 25710238
[No Abstract] [Full Text] [Related]
19. Parent Stress in a Randomized Clinical Trial of Atomoxetine and Parent Training for Children with Autism Spectrum Disorder.
Lecavalier L; Pan X; Smith T; Handen BL; Arnold LE; Silverman L; Tumuluru RV; Hollway J; Aman MG
J Autism Dev Disord; 2018 Apr; 48(4):980-987. PubMed ID: 29022125
[TBL] [Abstract][Full Text] [Related]
20. Effect of Atomoxetine on the Cognitive Functions in Treatment of Attention Deficit Hyperactivity Disorder in Children with Congenital Hypothyroidism: A Pilot Study.
Yang R; Gao W; Li R; Zhao Z
Int J Neuropsychopharmacol; 2015 Apr; 18(8):. PubMed ID: 25896257
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
